Today, the National Growth Fund announced that PharmaNL has met the conditions to convert the conditional allocation of €78.8 million into a definitive grant.
“We at PharmaNL are delighted with this news. Together with stakeholders, we can now begin implementing the ambitions of PharmaNL,” said Brigitte Drees, Director of Pivot Park.
Click here to view the official announcement from the Dutch government.
PharmaNL is a national public-private consortium comprising Leiden University Medical Center, Leiden University, Campus Groningen, and Pivot Park, working closely with FAST - Platform to Future Affordable Sustainable Therapies.
PharmaNL is kicking off with €80 million in funding from the National Growth Fund to invest in research facilities and human capital.
Source: PharmaNL
Who is developing the most impactful innovation in Life Sciences & Health in the Northern Netherlands? Five companies are in the running for the LIFE Science Innovation Award 2026: Flux Robotics, Limosa Immunodiagnostics, SPCTR, MimeCure and GlycanScan International. The nominees will present their innovations on Tuesday 22 September during the fifth edition of the LIFE Science Conference in Groningen. An independent jury will select the winner, who will receive a €10,000 cash prize.
ZonMw is expected to open the final call for proposals within the PharmaNL Shared Development Infrastructure (SDI) program line. This program line focuses on strengthening the infrastructure for the development, upscaling, and production of innovative medicines in the Netherlands.
As the largest medical sterilization centre in the Benelux, SteriNoord B.V. provides safe, reliable, and high-quality reprocessing of medical instruments. With state-of-the-art technology and a team of dedicated professionals, the organisation plays an essential role in supporting high-quality healthcare.
